CD155 (Ig-like domain, ligand)
Use this icon in our BioRender software along with 1000s of others. Create your next scientific figure in minutes!
SIGN UP FREE[{"image":"https://icons.biorender.com/w75xh75/5e348053cf9d2e00289a8905/cd266-ig-like-domain-ligand.png","waterMarkImage":"https://icons.biorender.com/w550xh620/5e348053cf9d2e00289a8905/cd266-ig-like-domain-ligand.png"},{"image":"https://icons.biorender.com/w75xh75/5e348053cf9d2e00289a8904/cd266-ig-like-domain-ligand.png","waterMarkImage":"https://icons.biorender.com/w550xh620/5e348053cf9d2e00289a8904/cd266-ig-like-domain-ligand.png"},{"image":"https://icons.biorender.com/w75xh75/5e348053cf9d2e00289a8903/cd266-ig-like-domain-ligand.png","waterMarkImage":"https://icons.biorender.com/w550xh620/5e348053cf9d2e00289a8903/cd266-ig-like-domain-ligand.png"},{"image":"https://icons.biorender.com/w75xh75/5e348053cf9d2e00289a8902/cd266-ig-like-domain-ligand.png","waterMarkImage":"https://icons.biorender.com/w550xh620/5e348053cf9d2e00289a8902/cd266-ig-like-domain-ligand.png"},{"image":"https://icons.biorender.com/w75xh75/5e348053cf9d2e00289a8901/cd266-ig-like-domain-ligand.png","waterMarkImage":"https://icons.biorender.com/w550xh620/5e348053cf9d2e00289a8901/cd266-ig-like-domain-ligand.png"},{"image":"https://icons.biorender.com/w75xh75/5e348053cf9d2e00289a8900/cd266-ig-like-domain-ligand.png","waterMarkImage":"https://icons.biorender.com/w550xh620/5e348053cf9d2e00289a8900/cd266-ig-like-domain-ligand.png"},{"image":"https://icons.biorender.com/w75xh75/5e348053cf9d2e00289a88ff/cd266-ig-like-domain-ligand.png","waterMarkImage":"https://icons.biorender.com/w550xh620/5e348053cf9d2e00289a88ff/cd266-ig-like-domain-ligand.png"},{"image":"https://icons.biorender.com/w75xh75/5e348053cf9d2e00289a88fe/cd266-ig-like-domain-ligand.png","waterMarkImage":"https://icons.biorender.com/w550xh620/5e348053cf9d2e00289a88fe/cd266-ig-like-domain-ligand.png"},{"image":"https://icons.biorender.com/w75xh75/5e348053cf9d2e00289a88fd/cd266-ig-like-domain-ligand.png","waterMarkImage":"https://icons.biorender.com/w550xh620/5e348053cf9d2e00289a88fd/cd266-ig-like-domain-ligand.png"},{"image":"https://icons.biorender.com/w75xh75/5e348053cf9d2e00289a88fc/cd266-ig-like-domain-ligand.png","waterMarkImage":"https://icons.biorender.com/w550xh620/5e348053cf9d2e00289a88fc/cd266-ig-like-domain-ligand.png"},{"image":"https://icons.biorender.com/w75xh75/5e348053cf9d2e00289a88fb/cd266-ig-like-domain-ligand.png","waterMarkImage":"https://icons.biorender.com/w550xh620/5e348053cf9d2e00289a88fb/cd266-ig-like-domain-ligand.png"},{"image":"https://icons.biorender.com/w75xh75/5e348053cf9d2e00289a88fa/cd266-ig-like-domain-ligand.png","waterMarkImage":"https://icons.biorender.com/w550xh620/5e348053cf9d2e00289a88fa/cd266-ig-like-domain-ligand.png"},{"image":"https://icons.biorender.com/w75xh75/5e348053cf9d2e00289a88f9/cd266-ig-like-domain-ligand.png","waterMarkImage":"https://icons.biorender.com/w550xh620/5e348053cf9d2e00289a88f9/cd266-ig-like-domain-ligand.png"},{"image":"https://icons.biorender.com/w75xh75/5e348053cf9d2e00289a88f8/cd266-ig-like-domain-ligand.png","waterMarkImage":"https://icons.biorender.com/w550xh620/5e348053cf9d2e00289a88f8/cd266-ig-like-domain-ligand.png"},{"image":"https://icons.biorender.com/w75xh75/5e348053cf9d2e00289a88f7/cd266-ig-like-domain-ligand.png","waterMarkImage":"https://icons.biorender.com/w550xh620/5e348053cf9d2e00289a88f7/cd266-ig-like-domain-ligand.png"},{"image":"https://icons.biorender.com/w75xh75/5e348053cf9d2e00289a88f6/cd266-ig-like-domain-ligand.png","waterMarkImage":"https://icons.biorender.com/w550xh620/5e348053cf9d2e00289a88f6/cd266-ig-like-domain-ligand.png"},{"image":"https://icons.biorender.com/w75xh75/5e348053cf9d2e00289a88f5/cd266-ig-like-domain-ligand.png","waterMarkImage":"https://icons.biorender.com/w550xh620/5e348053cf9d2e00289a88f5/cd266-ig-like-domain-ligand.png"},{"image":"https://icons.biorender.com/w75xh75/5e348053cf9d2e00289a88f4/cd266-ig-like-domain-ligand.png","waterMarkImage":"https://icons.biorender.com/w550xh620/5e348053cf9d2e00289a88f4/cd266-ig-like-domain-ligand.png"},{"image":"https://icons.biorender.com/w75xh75/5e348053cf9d2e00289a88f3/cd266-ig-like-domain-ligand.png","waterMarkImage":"https://icons.biorender.com/w550xh620/5e348053cf9d2e00289a88f3/cd266-ig-like-domain-ligand.png"},{"image":"https://icons.biorender.com/w75xh75/5e348053cf9d2e00289a88f2/cd266-ig-like-domain-ligand.png","waterMarkImage":"https://icons.biorender.com/w550xh620/5e348053cf9d2e00289a88f2/cd266-ig-like-domain-ligand.png"},{"image":"https://icons.biorender.com/w75xh75/5e348053cf9d2e00289a88f1/cd266-ig-like-domain-ligand.png","waterMarkImage":"https://icons.biorender.com/w550xh620/5e348053cf9d2e00289a88f1/cd266-ig-like-domain-ligand.png"}]
Keywords
CD226,CD155,ig-like domain,DNAM-1,DNAM1,PTA1,TLiSA1,PVR,HVED,NECL5,necl-5,PVS,tage4,poliovirus receptor,PVR cell adhesion molecule,ligand